"The Label Combination" trang 1 - tải miễn phí từ tailieuXANH
Multi-label classification for physical activity recognition from various accelerometer sensor positions

Multi-label classification for physical activity recognition from various accelerometer sensor positions
23    73    0
Final results from IMPROVE: A randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Final results from IMPROVE: A randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer
12    62    0
Study protocol for an open-label, singlearm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma

Study protocol for an open-label, singlearm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma
8    103    0
Combination therapy with erythropoietin, magnesium sulfate and hypothermia for hypoxic-ischemic encephalopathy: An open-label pilot study to assess the safety and feasibility

Combination therapy with erythropoietin, magnesium sulfate and hypothermia for hypoxic-ischemic encephalopathy: An open-label pilot study to assess the safety and feasibility
6    59    0
COMBImage2: A parallel computational framework for higher-order drug combination analysis that includes automated plate design, matched filter based object counting and temporal data mining

COMBImage2: A parallel computational framework for higher-order drug combination analysis that includes automated plate design, matched filter based object counting and temporal data mining
20    60    0
Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/ extended-release hydrocodone bitartrate/ acetaminophen (MNK-155) under fed and fasted conditions: Two randomized open-label trials

Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/ extended-release hydrocodone bitartrate/ acetaminophen (MNK-155) under fed and fasted conditions: Two randomized open-label trials
10    33    0
Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: Protocol for an open-label, non-randomised, Phase 2 study

Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: Protocol for an open-label, non-randomised, Phase 2 study
6    48    0
Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): A phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum

Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): A phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum
10    51    0
Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: Final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)

Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: Final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)
8    65    0
LncRNA-miRNA interaction prediction through sequence-derived linear neighborhood propagation method with information combination

LncRNA-miRNA interaction prediction through sequence-derived linear neighborhood propagation method with information combination
12    50    2
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.